Dr. Gail Musen’s Research into Cognitive Function in People with Type 2 Diabetes Receives Alzheimer’s Association Grant :
BOSTON – (March 19, 2015) – In a ceremony today, the Alzheimer’s Association awarded Gail Musen, Ph.D, Assistant Investigator in the Section on Clinical, Behavioral and Outcomes Research at Joslin Diabetes Center and Assistant Professor in Psychiatry at Harvard Medical School, the Investigator-Initiated Research Grant. This is one of the largest grants given out by the association and it was awarded to Dr. Musen for her research into the effects of maintaining cognitive function for people with type two diabetes.
Joslin Partners with Sunshine Insurance Group Corporation to Develop a Diabetes Center of Excellence in China:
Beijing/ Boston – (March 10, 2015) – Joslin Diabetes Center and Sunshine Insurance Group Corporation Limited have announced today that they are collaborating to design and develop a Diabetes Center of Excellence in Weifang, Shandong Province, China. Located in Boston, Massachusetts, Joslin is the world's leading diabetes research, clinical care and education organization dedicated to the prevention, treatment and cure of diabetes. Joslin is an independent, non-profit institution affiliated with Harvard Medical School. Sunshine, founded in 2005, is one of China’s largest insurance companies, providing property, and casualty and life insurance service nationwide, the company is now actively getting into healthcare industry.
Joslin Researchers Conduct First Trial Directly Comparing Drugs for Diabetic Macular Edema and Find All are Effective :
BOSTON – (February 19, 2015) – In the first clinical trial directly comparing three drugs most commonly used to treat diabetic macular edema, researchers found all were effective in improving vision and preventing vision loss. However, one drug, aflibercept, provided greater improvement for people with more severe vision loss when treatment was initiated. The trial was conducted by the National Eye Institute Diabetic Retinopathy Clinical Research Network (DRCR.net) including researchers from Joslin Diabetes Center. The results appeared in the February online edition of the New England Journal of Medicine.
Scientists use MRI to visualize pancreas inflammation:
BOSTON – (February 17, 2015) – A pilot study led by researchers at Joslin Diabetes Center has revealed that it is possible to use magnetic resonance imaging (MRI) to "see" the inflammation in the pancreas that leads to type 1 diabetes. This discovery could be a boon for research on methods to slow or halt the disease at an early stage, and could also guide insights into how diabetes progresses.
Joslin Diabetes Center Earns NCQA’s Highest Level of National Recognition for Quality Care:
BOSTON — (January 8, 2015) – Joslin Diabetes Center announced today that the Joslin Clinic has received level-three recognition, the highest level of recognition, from the National Committee for Quality Assurance (NCQA) as a Patient-Centered Specialty Practice (PCSP) for its responsiveness to patients and medical colleagues, cooperation and integration with other health care groups, and dedication to continuous improvement.
Drug Turns on Brown Fat and Burns Calories in People:
BOSTON – (January 6, 2015) – In an early phase clinical trial led by Joslin Diabetes Center researchers, an oral drug approved for treating incontinence successfully activated brown fat – a form of fat that can help to expend energy. At peak effect, the drug boosted energy consumption by more than a tenth in the trial volunteers, suggesting that it might help in losing weight.
Diabetic Eye Disease Treatment Discovered:
BOSTON – (September 10, 2014) – George King, M.D., Chief Scientific Officer and Senior Vice President of Joslin Diabetes Center and Professor of Medicine at Harvard Medical School, and Lloyd Paul Aiello, M.D., Ph.D., Director of the Beetham Eye Institute (BEI) and Professor of Ophthalmology at Harvard Medical School, were among seven individuals, including colleagues from Massachusetts Eye and Ear Infirmary, Genentech and UC San Diego, to receive the 2014 Antonio Champalimaud Vision Award for their contributions toward the discovery of treatments inhibiting vascular endothelial growth factor (VEGF) for ocular diseases. Drs. King and Aiello performed pivotal work in this area regarding the retinal diseases of proliferative diabetic retinopathy (PDR) and diabetic macular edema (DME).
Scientists Raise Alarm that Shortage of Human Islet Cells Will Slow Diabetes Research:
BOSTON – (November 20, 2014) – Rohit Kulkarni, M.D., Ph.D., Senior Investigator in the Section on Islet Cell and Regenerative Biology at Joslin Diabetes Center and Associate Professor at Harvard Medical School, coauthored a paper that was published today in Diabetes, which voiced concerns about the increasing difficulty of access to high quality islet cells for diabetes research. Andrew Stewart, M.D., Director of the Diabetes, Obesity and Metabolism Institute at of Mount Sinai Hospital in New York, served as the other lead author.
Dr. Robert G. Spiro, M.D., Receives Lifetime Achievement Award:
BOSTON — (November 12, 2014)— Dr. Robert G. Spiro has been awarded the Joslin Diabetes Center Lifetime Achievement Award for his significant contributions to the fight against diabetes. This award goes to people who have had profound influence on the Joslin Diabetes Center in its ongoing efforts in the prevention and treatment of diabetes.
Vicki J. Brown Joins Joslin Diabetes Center As Chief Marketing Officer:
BOSTON – (November 6, 2014) – Joslin Diabetes Center today announced that Vicki J. Brown has joined its executive team as Chief Marketing Officer to provide strategic leadership and proactive management for all marketing activities across Joslin’s patient care and research organizations.
Edward Horton, M.D. Receives JK Lilly Award for Outstanding Service:
BOSTON – (November 4, 2014) – Edward Horton, M.D., Senior Investigator at Joslin Diabetes Center and Professor of Medicine at Harvard Medical School, was presented with the 2014 Josiah Kirby Lilly Award for outstanding service to all those affected by diabetes on Saturday, November 1 by the American Diabetes Association.
Johnson & Johnson Diabetes Solutions Companies Join The Joslin Institute for Technology Translation (JITT) As Founding Members:
BOSTON, October 30, 2014 – The Joslin Institute for Technology Translation (JITT) today announced that three Johnson & Johnson Diabetes Solutions Companies, LifeScan, Inc., Animas Corporation and Calibra Medical, Inc., have joined JITT as Founding Members and as members of JITT’s Advisory Board. JITT, a recently introduced innovation group of Joslin Diabetes Center, is focused on leveraging the potential of technology with the introduction of clinical solutions, decision support tools and the advancement of digital health to improve the lives of people with diabetes.
In Joslin Trial, Asian Americans Lower Insulin Resistance on Traditional Diet:
BOSTON – September 17, 2014 – Why are Asian Americans at higher risk of developing type 2 diabetes than Caucasian Americans, and prone to develop the disease at lower body weights? One part of this puzzle may lie in the transition from traditional high-fiber, low-fat Asian diets to current westernized diets, which may pose extra risks for those of Asian heritage, says George King, M.D., Senior Vice President and Chief Scientific Officer at Joslin Diabetes Center and the senior author of the study.
Research Evidence Affirms that Good Nutrition Can Help Prevent and Control Type 2 Diabetes:
BOSTON – August 28, 2014 – In a comprehensive review of recent randomized clinical trials and observational studies of diabetes and nutrition, Joslin Diabetes Center and Harvard School of Public Health investigators have identified specific foods and dietary patterns that are beneficial in preventing and controlling diabetes. The findings were published June 7, 2014 in Lancet.
Joslin Scientists Create the First iPS Cells to Offer Human Model of Insulin Resistance:
BOSTON – July 24, 2014 –Japanese biologist Shinya Yamanaka won a Nobel Prize in 2012 for discovering how to create “induced pluripotent stem cells” (iPSCs), cells derived from normal adult cells that have the ability to differentiate into almost any other kind of cells. Scientists at Joslin Diabetes Center now have created the first iPSCs that offer a human model of insulin resistance, a key driver of type 2 diabetes.
ADA Type 1 Diabetes Position Statement Changes A1C Recommendations for Pediatric Patients:
BOSTON – (July 18, 2014) – The American Diabetes Association released a position statement outlining care protocols for persons with type 1 diabetes. The guidelines were officially released at the 2014 ADA Annual Conference in San Francisco this past June. The position statement covers care recommendations for all age ranges, from early childhood to adulthood and into the geriatric years.
Inherited ‘Memory’ of Environmental Impact on Health May Be Limited:
BOSTON – (July 10, 2014) – When a pregnant mother is undernourished, her child is at a greater than average risk of developing obesity and type 2 diabetes, in part due to so-called ‘epigenetic’ effects. A new study in mice demonstrates that this ‘memory’ of nutrition during pregnancy can be passed through sperm of male offspring to the next generation, increasing risk of disease for her grandchildren as well. In other words, to adapt an old maxim, ‘you are what your grandmother ate’. The study has also raised questions over how epigenetic effects are passed down from one generation to the next – and for how long they will continue to have an impact.
Diabetes Research News:
BOSTON – July 1, 2014 – Building upon their earlier research on the biology of fat metabolism, Joslin scientists discovered that microRNAs –small RNA molecules that play important roles in regulation in many types of tissue – play a major role in the distribution and determination of fat cells and whole body metabolism. Also, the study is the first to reveal that microRNAs (miRNAs) influence the development of lipodystrophy (abnormal fat accumulation) which affects many people with HIV receiving anti-retroviral therapy. The findings appear in the August issue of the Journal of Clinical Investigation.
Joslin and Steno Establish Partnership to Improve Clinical Outcomes and to Strengthen Education in Developing Countries:
BOSTON (June 13, 2014) – Joslin Diabetes Center and Steno Diabetes Center today announced a long-term partnership to improve clinical outcomes in diabetes care. The partnership was announced at the American Diabetes Association’s 74th Scientific sessions in San Francisco and builds on a long tradition of knowledge sharing and collaboration within diabetes care and research. “I am very happy to announce this partnership which builds on the historic relations between these two pioneering institutions”, says CEO and Head of Steno Diabetes Center, John Nolan. “It’s an important step to improve patient care and to disseminate knowledge and best practice within developing countries.”
Tandem Diabetes Care, Inc. Joins The Joslin Institute for Technology Translation (JITT) As Founding Member:
BOSTON (June 12, 2014) – Joslin Diabetes Center today announced that Tandem Diabetes Care®, Inc., a medical device company that designs and manufactures products for people with insulin-dependent diabetes, has joined the Joslin Institute for Technology Translation (the “Institute” or JITT) as a Founding Member and is a member of its Advisory Board. A new department of Joslin Diabetes Center, the Joslin Institute for Technology Translation is focused on leveraging the potential of technology with the introduction of clinical solutions and digital health to improve the lives of people with diabetes.
Joslin Institute for Technology Translation (JITT) and Glooko, Introduce Hypoglycemia Awareness Product Designed to Improve Hypoglycemia Self-Management for People with Diabetes:
(Boston, Massachusetts and Palo Alto, California) June 11, 2014 - Joslin Institute for Technology Translation (JITT) at Joslin Diabetes Center, the world’s preeminent institution in diabetes research and clinical care, and Glooko Inc., a mobile, cloud based diabetes management system announced the release of their jointly developed Joslin HypoMap™ powered by Glooko™. Joslin HypoMap, powered by Glooko, is designed to improve health outcomes and reduce costs for use by patients and providers to improve self-management of hypoglycemia (low blood glucose events) as part of their diabetes management program. The Joslin HypoMap will be launched at the American Diabetes Association’s 74th Scientific Sessions, occurring June 13-17, 2014 in San Francisco. Visit us at booth #2149-Joslin Diabetes Center or #2241-Glooko.
Joslin Diabetes Center Introduces Joslin Institute for Technology Translation (JITT) :
BOSTON (June 10, 2014) – Joslin Diabetes Center today announced the introduction of the Joslin Institute for Technology Translation (the “Institute” or JITT), a new division of Joslin Diabetes Center that formalizes the delivery of Joslin’s clinical solutions to medical device and technology companies. In addition, it was announced that Dexcom, Inc., a San Diego-based maker of continuous glucose monitoring systems for patients and blood glucose monitoring systems for healthcare providers in hospital settings, has joined to become the first Founding Member of the JITT and is a member of the Institute’s Advisory Board.
Dr. Lori Laffel and Dr. Howard Wolpert to be Honored at JDRF Boston Gala:
BOSTON – (May 13, 2014) – Joslin Diabetes Center announced today that Lori Laffel, M.D., M.P.H., Chief of the Pediatric, Adolescent and Young Adult Section at Joslin and Associate Professor of Pediatrics at Harvard Medical School, and Howard Wolpert, M.D., Director of the Joslin Institute for Technology Translation (JITT) and Associate Professor of Medicine at Harvard Medical School, will be honored as Research Champions at the JDRF’s upcoming Boston Gala. They will receive the Nancy Jones Diabetes Champion Award for Research at the 32nd Annual Boston Gala on May 17, 2014 at the Boston Marriott Copley Place.
Joslin Medalists Maintain High Levels of Cells Involved in Blood-Vessel Repair:
BOSTON – April 29, 2014 – Decades after being diagnosed with type 1 diabetes, some Joslin 50-Year Medalists, who have lived 50 or more years with the disease, maintain certain types of blood cells that could help to repair blood vessels. The persistence of these endothelial progenitor cells (EPCs) and circulating progenitor cells (CPCs) may help to explain why these patients generally suffer less from cardiovascular and diabetic kidney disease than expected for those who have the disease for many years.
Governor Patrick Joins Joslin Diabetes Center and the MLSC in Officially Opening Translational Center for the Cure of Diabetes:
BOSTON, April 8, 2014 — Today, Joslin Diabetes Center opened its new Translational Center for the Cure of Diabetes at its campus in the heart of Boston’s Longwood Medical Area. Governor Deval L. Patrick cut the ceremonial ribbon, along with Joslin President & CEO, John Brooks and the President & CEO of the Massachusetts Life Sciences Center, Susan Windham-Bannister, Ph.D. In January 2012, Joslin, the world leader in diabetes research and care, received a $5 million grant from the Massachusetts Life Sciences Center (MLSC), among the highest amounts ever received to support diabetes research in Massachusetts. The grant was matched with $5.8 million in funds raised from generous Joslin donors, and a total of $10.8 million was used to build the comprehensive center.
Joslin Diabetes Center Renews Alliance with Sunstar, Inc., a Leading Company in Oral Health Care :
Etoy/ Boston – (April 7, 2014) – Sunstar Inc., a Switzerland-based, leading company in oral health care and one of the first businesses to emphasize an integrated approach to the relationship between oral health and systemic disease, and Joslin Diabetes Center, the world's largest diabetes research and clinical care organization dedicated to the prevention, treatment and cure of diabetes, have renewed their commitment to the Joslin Sunstar Diabetes Education Initiative (JSDEI).
TVM Capital Healthcare Partners Announces Alliance with Joslin Diabetes Center, World Leading Diabetes Organization:
Dubai/ Boston - (March 17, 2014) - TVM Capital Healthcare Partners, the region’s first private equity firm dedicated exclusively to the healthcare sector, has signed an affiliation with Joslin Diabetes Center. Located in Boston, Massachusetts, Joslin is the world's leading diabetes research, clinical care and education organization dedicated to the prevention, treatment and cure of diabetes. Joslin is an independent, non-profit institution affiliated with Harvard Medical School.
Beetham Eye Institute at Joslin Diabetes Center Cited for Outstanding Treatment for Diabetic Retinopathy:
BOSTON – (March 12, 2014) – The Beetham Eye Institute (BEI) at Joslin Diabetes Center has been recognized as one of the top institutions worldwide for research and treatment of diabetic retinopathy by Expertscape. In addition, Lloyd P. Aiello, M.D., Ph.D., Director of the BEI and Professor of Ophthalmology at Harvard Medical School has been recognized as one of the top three specialists in diabetic retinopathy worldwide.
Study Demonstrates Care Managers in Patient-Centered Medical Homes Increase Improvements in Diabetes Patient Outcomes :
BOSTON – January 21, 2013 – Patient centered medical homes (PCMHs) have been found to be an effective way to help care for patients with chronic diseases such as diabetes. Dr. Robert Gabbay, M.D., Ph.D., FACP, Chief Medical Officer and Senior Vice President at Joslin Diabetes Center, Harvard Medical School, and his team conducted a study that shows the strategic placement of care managers in PCMHs can further improve patient outcomes for high-risk diabetes patients.
Joslin Diabetes Center Teams with Glooko on Next Generation Diabetes Management Solution:
Palo Alto, California. & Boston, Massachusetts – January 21, 2014 – Joslin Diabetes Center, the world’s pre-eminent institution in diabetes research and clinical care, and Glooko Inc. have signed an agreement to jointly deploy an advanced diabetes management technology platform that will allow patients to share diabetes management data and in turn use that data through decision-making algorithms for optimal and predictive diabetes care. Glooko and Joslin will jointly provide a diabetes management solution globally to health systems, governments and payer groups aiming to improve health outcomes and lower costs.
Joslin Finds Metabolic Clues to Diabetic Kidney Failure:
BOSTON – January 15, 2013 – About 33 percent of people with type 2 diabetes suffer kidney damage that progresses to end stage renal disease (ESRD), at which point they require either dialysis or kidney transplantation. Scientists have thought that this kidney disease is driven by damage to the glomeruli, blood vessels in the kidney, which spill the protein albumin into the urine. Current treatments targeting the resulting “albuminuria” do not prevent kidney failure.
Joslin Researchers Determine Hormone Linked to Improved Glucose Metabolism Activates Browning of Fat:
BOSTON – (January 9, 2013) – Researchers at Joslin Diabetes Center have discovered that a hormone long associated with weight loss and improved glucose metabolism is linked to activation of calorie-burning brown fat. This finding could have implications for production of new medications for type 2 diabetes and obesity. The results are published in the January issue of The Journal of Clinical Investigation in a paper titled “Interplay between FGF21 and Insulin Action in the Liver for the Regulation of Metabolism.”
Joslin Diabetes Center launches pilot of JCAT™ quality analysis tool at Truman Medical Centers:
BOSTON – April 1, 2013 – Joslin Diabetes Center, an affiliate of Harvard Medical School, has launched a pilot program in conjunction with Truman Medical Centers, the primary teaching hospital for the University of Missouri-Kansas City Schools of Medicine to test the capabilities of a novel and innovative care analytics tool called the Joslin Clinical Analytical Tool (JCAT™).
Joslin Supports FDA Ban on Artificially-Made Trans Fats:
BOSTON – (November 25, 2013) – On Nov. 7, the Food and Drug Administration (FDA) put one of the final nails in the coffin of artificially-made trans fats with its decision to ban them from our nation’s food supply. The Joslin applauds the FDA’s decision and supports efforts to move this initiative forward as quickly as possible.
Joslin and WorldOne Launch Diabetes HUB on Sermo:
BOSTON – (November 20, 2013) – WorldOne and Joslin Diabetes Center announced that they have launched the Diabetes HUB, an online clinical and educational resource. The HUB is housed on Sermo and will allow for close collaboration and information sharing between diabetes experts and primary care physicians (PCP).
National Diabetes Coalition Urges Caution on New Population Survey:
Boston – October 18, 2013 – Today, the Centers for Disease Control (CDC) released the National Health and Nutritional Examination Survey (NHANES) with additional data briefs on hypertension, cholesterol and obesity among adults in the U.S. by age, gender, race and ethnicity. This detailed national survey of health characteristics, for the first time, includes important health status and information on Asian Americans (AA). We applaud the CDC for including Asian Americans, who are the fastest growing minority in this country. However, the conclusion of the analysis suggests that the AA population has a significantly lower rate of obesity among the various ethnic groups, implying that the AA population will also have fewer health problems associated with obesity such as diabetes, high blood pressure, kidney disease and cardiovascular disease.
Joslin Boosts Insight into Role of Brain Stress in Obesity and Type 2 Diabetes Development:
BOSTON – October 1, 2013 – Joslin researchers have gained new insights into how obesity and type 2 diabetes can create a stress response in the brain, especially in the hypothalamus (the brain region that regulates appetite and energy production), that may contribute to altering metabolism throughout the body. The findings are reported in the October issue of the Journal of Clinical Investigation.
Joslin Receives $24.3 Million Grant from the NIH for Diabetic Kidney Disease Study:
BOSTON – (September 26, 2013) The National Institutes of Health awarded Joslin Diabetes Center $24.3 million to fund a clinical trial to study a potential treatment for kidney disease in people with type 1 diabetes. Alessandro Doria, M.D., Ph.D., M.P.H., an Investigator in the Section on Genetics and Epidemiology, Associate Professor of Medicine at Harvard Medical School and Associate Professor in the Department of Epidemiology at the Harvard School of Public Health, will lead the trial together with his co- Principal Investigator, Michael Mauer, M.D., Professor of Pediatrics and Medicine at the University of Minnesota Medical School.
Joslin Diabetes Center Announces Collaboration with Good Measures:
BOSTON – (September 6, 2013) – Good Measures and Joslin Diabetes Center announced today that they have reached an agreement, aimed at incorporating Joslin’s nutritional guidelines, meal plans, exercise recommendations and other relevant resources into Good Measures’ product and service offerings.
Genetic Variant Associated with Coronary Heart Disease in T2D:
BOSTON -- August 29, 2013 -- Joslin scientists, in collaboration with researchers from the Harvard School of Public Health and Italian research institutes, have identified a previously unknown genetic variant associated with an increased risk of coronary heart disease (CHD) in type 2 diabetic patients. This discovery has the potential to lead to the development of new treatments for CHD in diabetic patients. The findings appear in the [month] issue of the Journal of the American Medical Association (JAMA).
Joslin Diabetes Center Honors C. Ronald Kahn, M.D. at 2013 International Symposium:
BOSTON – (August, 19 2013) – Joslin Diabetes Center, a global leader in diabetes research, care and education, will honor C. Ronald Kahn, M.D. at the 2013 International Symposium on Diabetes: New Discoveries on the Roles of Environment and Genetics in Insulin Action, which takes place on October 31, 2013 through November 2, 2013 at the Boston Seaport Hotel.
C. Ronald Kahn, M.D., Receives Wallace H. Coulter Lectureship Award:
BOSTON – July 24, 2013 – The American Association for Clinical Chemistry (AACC) will present C. Ronald Kahn, M.D., of Newton, MA, with the Wallace H. Coulter Lectureship Award at its 2013 Annual Meeting and Clinical Exposition in Houston, Texas on July 28. The Wallace H. Coulter Lectureship Award goes to an individual who has demonstrated a lifetime commitment to, and made important contributions that have had a significant impact on education, practice and/or research in laboratory medicine or patient care. Dr. Kahn was selected to receive this award based on his 40 year commitment to the field of diabetes and obesity research, in particular his significant work in insulin signal transduction and the mechanisms of altered insulin signaling in disease.
Joslin Scientists Find that Salsalate Lowers Blood Glucose in Type 2 Diabetes:
BOSTON – July 1, 2013 - Joslin scientists report that salsalate, a drug used to treat arthritis, lowers blood glucose and improves glycemic control in type 2 diabetes. These findings, which appear in the Annals of Internal Medicine, provide additional evidence that salsalate may be an effective drug to treat type 2 diabetes.
Joslin Study Finds Connection Between Erectile Dysfunction and Cardiovascular Disease in Joslin Medalists :
BOSTON – June 26, 2013 – A number of studies have established the connection between erectile dysfunction and cardiovascular disease in men starting in their fourth decade of life. However, a new study at Joslin Diabetes Center that examined the connection between erectile dysfunction and cardiovascular disease in Joslin Medalists – people living with type 1 diabetes for 50 or more years –showed that a history of erectile dysfunction is independently associated with cardiovascular disease. This suggests that sexual dysfunction can predict cardiovascular disease in those with type 1 diabetes for 50 or more years, but who are relatively free of microvascular diseases.
Robert A. Gabbay, M.D., Ph.D., Joins Joslin Diabetes Center as Chief Medical Officer:
BOSTON - June 24, 2013 - Robert A. Gabbay, M.D., Ph.D., has been appointed as Chief Medical Officer and Senior Vice President of Joslin Diabetes Center. Joslin Diabetes Center is an independent institution affiliated with Harvard Medical School and the world's largest diabetes clinic, diabetes research center and provider of diabetes education. Joslin is dedicated to ensuring that people with diabetes live long, healthy live and to offering real hope and progress toward diabetes prevention and, ultimately, a cure.
New Joslin Study Shows Exercise Creates “Good Fat”:
BOSTON – June 21, 2013 – Joslin Diabetes Center scientists have demonstrated through two new studies of mice and humans that exercise can train fat to behave differently than the fat that develops from sedentary behavior, and this “good fat” may stimulate metabolic improvements in other tissues.
Joslin Scientists Advance Understanding of Human Brown Adipose Tissue and Grow New Cells:
BOSTON – April 22, 2013 – Joslin scientists report significant findings about the location, genetic expression and function of human brown adipose tissue (BAT) and the generation of new BAT cells. These findings, which appear in the April 2013 issue of Nature Medicine, may contribute to further study of BAT’s role in human metabolism and developing treatments that use BAT to promote weight loss.
Joslin Researchers Identify Important Factor in Fat Storage and Energy Metabolism:
BOSTON – January 8, 2013 -- As part of their ongoing research on the physiologic factors that contribute to the development of obesity, Joslin Diabetes Center scientists have identified a cell cycle transcriptional co-regulator – TRIP-Br2 – that plays a major role in energy metabolism and fat storage. This finding has the potential to lead to new treatments for obesity. The study is being published today ahead of print by Nature Medicine.
Brown Adipose Tissue Has Beneficial Effects on Metabolism & Glucose Tolerance:
BOSTON – December 10, 2012 – Joslin Diabetes Center scientists have demonstrated that brown adipose tissue (BAT) has beneficial effects on glucose tolerance, body weight and metabolism. The findings, which may lead to new treatments for diabetes, appear in the upcoming issue of the Journal of Clinical Investigation.
Joslin Researchers Increase Understanding of Genetic Risk Factor for Type 1 Diabetes:
BOSTON – November 28, 2012 – As part of their ongoing research on the role of genes in the development of type 1 diabetes, Joslin Diabetes Center scientists, in collaboration with scientists at the University of Würzburg, have demonstrated how a genetic variant associated with type 1 diabetes and other autoimmune diseases influences susceptibility to autoimmunity. The findings appear in the upcoming issue of Diabetes.
NIH Awards $9.5 Million Grant to Joslin Diabetes Center to Support Diabetes Research:
BOSTON – October 3, 2012 - Joslin Diabetes Center, Boston, Massachusetts, has been awarded a $9.5 million, multi-year Diabetes Research Center (DRC) grant from the National Institutes of Diabetes, Digestive and Kidney Disorders (NIDDK) of the National Institute of Health (NIH). This marks the 26th year in which Joslin has been awarded the DRC grant.
Joslin Scientists Identify Molecular Process in Fat Cells That Influences Stress and Longevity:
BOSTON – September 26, 2012 - As part of their ongoing research investigating the biology of aging, the greatest risk factor for type 2 diabetes and other serious diseases, scientists at Joslin Diabetes Center have identified a new factor -- microRNA processing in fat tissue – which plays a major role in aging and stress resistance. This finding may lead to the development of treatments that increase stress resistance and longevity and improve metabolism. The findings appear in the September 5 online edition of Cell Metabolism.
Joslin Diabetes Center Announces Alliance with Mass Eye and Ear:
BOSTON -- September 4, 2012 -- Massachusetts Eye and Ear and Joslin Diabetes Center announced today that they have reached agreement to form a clinical and research alliance, aimed toward providing coordinated high quality care to eye patients throughout greater Boston, especially those with or at-risk for diabetes-related eye disease.
Joslin Scientists Identify Biological Mechanisms That Affect Diabetic Nephropathy:
BOSTON -- July 23, 2012 -- Scientists at Joslin Diabetes Center have identified biological mechanisms by which glucagon-like peptide-1 (GLP-1), a gut hormone, protects against kidney disease, and also mechanisms that inhibit its actions in diabetes. The findings, which are reported today online by Diabetes, may lead to the development of new therapeutic agents that harness the actions of GLP-1 to prevent the harmful effects of hyperglycemia on renal endothelial cells.
Joslin Convenes Diabetes Innovation Conference:
BOSTON -- July 18, 2012 -- The diabetes epidemic demands a powerful response from leaders in the diabetes community, nationally and globally. To this end, for the first time in its 114 year history, Joslin Diabetes Center, an affiliate of Harvard Medical School will convene all stakeholders for a groundbreaking, immersive activity over 3 days in September called Diabetes Innovation 2012 (September 23-25, 2012 at the Hyatt Crystal City in Arlington, VA).
Study: Short-Term Intensive Weight Loss Program Works For Four Years:
PHILADELPHIA -- June 12, 2012 -- A study by a team of clinicians and researchers at the Joslin Diabetes Center in Boston has shown for the first time that patients with diabetes who enrolled in a short-term intensive weight management program were able to lose weight and keep it off on their own for four years. The findings suggest an alternative course to bariatric surgery in the fight against type 2 diabetes.
Joslin Diabetes Center Receives $5 million Grant for Innovative Diabetes Project:
BOSTON – May 9, 2012 – Joslin Diabetes Center, Boston, Mass., has been awarded a $5 million 3-year grant from the Center for Medicare and Medicaid Innovation to expand their “On the Road” program for community-based diabetes education, field testing, and risk assessment. Joslin Diabetes Center is the world’s largest diabetes research and care organization and is affiliated with Harvard Medical School.
Joslin Scientists Identify Important Mechanism That Affects the Aging Process:
BOSTON – May 1, 2012 – Scientists at Joslin Diabetes Center have identified a key mechanism of action for the TOR (target of rapamycin) protein kinase, a critical regulator of cell growth which plays a major role in illness and aging. This finding not only illuminates the physiology of aging but could lead to new treatments to increase lifespan and control age-related conditions, such as cancer, type 2 diabetes, and neurodegeneration.
Joslin Partners with Ember Therapeutics to Develop Drug Treatment Approaches from “Brown Fat” Findings:
BOSTON — March 28, 2012 — Joslin Diabetes Center and Ember Therapeutics, Inc. today announced an agreement aimed at utilizing “brown fat,” a type of fat that helps increase energy expenditure within the body, as a novel technique for managing obesity and diabetes. Joslin’s Chief Academic Officer, Dr. Ronald Kahn and other Joslin faculty, Drs. Yu-Hua Tseng and Aaron Cypess, have performed pioneering work in this field over the past several years, and were the first to show that a natural protein called BMP7 can help modulate the levels of brown fat.
Joslin Study Finds Excess Insulin Levels an Unlikely Cause of Atherosclerosis:
Boston – March 22, 2012 – A number of studies have shown that excess insulin circulating in the bloodstream is a major independent risk factor for cardiovascular disease. However, a new study from Joslin Diabetes Center finds that this condition, called hyperinsulinemia, is itself not a cause of atherosclerosis.
Rick Markello Appointed Chief Operating Officer:
BOSTON – March 1, 2012 – Rick Markello, of Worcester, Massachusetts, has been appointed Chief Operating Officer (COO) of Joslin Diabetes Center in Boston, Massachusetts. Joslin is the largest diabetes research and clinical care center in the world and is a teaching affiliate of the Harvard Medical School.
C. Ronald Kahn, M. D., Appointed Chief Academic Officer:
BOSTON – January 30, 2012 – C. Ronald Kahn, M.D., of Newton, Massachusetts, has been appointed Chief Academic Officer (CAO) of Joslin Diabetes Center, the world’s largest diabetes clinical care and research organization and an affiliate of Harvard Medical School.
Joslin Study Identifies Novel Markers as Key Indicators of Future Renal Failure in Diabetes:
Boston, MA —January 19, 2012 —Scientists at Joslin Diabetes Center have identified two novel markers that, when elevated in the blood stream, can predict accurately the risk of renal (kidney) failure in patients with Type 1 and Type 2 diabetes. The findings have immediate diagnostic implications and can be used for the development of new therapies to prevent or postpone the progression of renal disease in diabetes.
Joslin Champions Diabetes Prevention:
BOSTON (MA) — January 12, 2012 — In a statement released today by Joslin Diabetes Center in Boston, physicians at the Harvard Medical School-affiliated research and clinical care center strongly disagreed with comments made recently by Richard Kahn, M.D., a former executive of the American Diabetes Association.
Study Finds Age-related Effects in MS may be Reversible:
BOSTON – January 6, 2012 – Scientists at Joslin Diabetes Center, Harvard University, and the University of Cambridge have found that the age-related impairment of the body’s ability to replace protective myelin sheaths, which normally surround nerve fibers and allow them to send signals properly, may be reversible, offering new hope that therapeutic strategies aimed at restoring efficient regeneration can be effective in the central nervous system throughout life.
Joslin Researchers Uncover Mechanism That Arrests Cell Death Protein During Embryonic Development:
BOSTON, MA – December 28, 2011 - In a study published today in PLoS ONE, a team from Joslin Diabetes Center, headed by Mary R. Loeken, Ph. D., made a significant advance toward understanding the molecular mechanisms behind the elevated risk of birth defects among babies born to mothers with diabetes. They uncovered the mechanism by which Pax3, a protein whose production is reduced in embryos of diabetic mothers, functions and stops the activity of the cell-death protein p53.
Joslin Study Identifies the Cause of Diabetes Misdiagnosis among Asian Americans:
BOSTON, MA – December 2, 2011 - Researchers at Joslin Diabetes Center have determined key differences between Type 1 and Type 2 diabetes in the Asian American population. This study, published today in PLoS ONE, identified ways to differentiate the types of diabetes, which can be clinically similar in young Asian Americans.
Joslin Diabetes Center Awarded Full Funding for Research in CME Outcomes Methods:
BOSTON - November 28, 2011 - Joslin Diabetes Center, an affiliate of Harvard Medical School, has launched a landmark research initiative to establish accuracy and predictive value of current assessment methodologies for CME (Certified Continuing Medical Education) in order to inform ongoing efforts to improve diabetes care.
Unlocking the Genetic and Molecular Mystery of Soft-tissue Sarcoma:
BOSTON - November 30, 2011 - Scientists at Joslin Diabetes Center in Boston have uncovered important molecular and genetic keys to the development of soft-tissue sarcomas in skeletal muscle, giving researchers and clinicians additional targets to stop the growth of these often deadly tumors.
Joslin Study Finds Clue to Birth Defects in Babies of Mothers with Diabetes:
BOSTON – October 17, 2011 — In a paper published today in Diabetologia, a team at Joslin Diabetes Center, headed by Mary R. Loeken, PhD, has identified the enzyme AMP kinase (AMPK) as key to the molecular mechanism that significantly increases the risk of neural tube defects such as spina bifida and some heart defects among babies born to women with diabetes.
Joslin Researchers Identify Pathways Leading to Activation of ‘Good’ Fat:
BOSTON – September 20, 2011 – Researchers at the Joslin Diabetes Center have identified for the first time two molecular pathways that are critical to activating a type of “good” fat found in the body, a discovery that could play an important role in the fight against obesity and diabetes.
Medical School Dean Elected to Board of Joslin Diabetes Center:
Peter S. Amenta, MD, PhD, dean of UMDNJ-Robert Wood Johnson Medical School, has been elected to the Board of Trustees of the Joslin Diabetes Center for a three-year term. The center, affiliated with Harvard Medical School, is the world's largest diabetes clinic, diabetes research center and provider of diabetes education. Joslin is dedicated to ensuring that people with diabetes live long, healthy lives and to offering real hope and progress toward diabetes prevention and, ultimately, a cure.
“Good Fat” Most Prevalent in Thin Children:
BOSTON (August 11, 2011) – Researchers at Joslin Diabetes Center and Children’s Hospital Boston have shown that a type of “good” fat known as brown fat occurs in varying amounts in children – increasing until puberty and then declining -- and is most active in leaner children.
New Link Found Between Obesity and Insulin Resistance:
BOSTON – 2 August, 2011 – Obesity is the main culprit in the worldwide avalanche of type 2 diabetes. But how excess weight drives insulin resistance, the condition that may lead to the disease, is only partly understood. Scientists at Joslin Diabetes Center now have uncovered a new way in which obesity wreaks its havoc, by altering the production of proteins that affect how other proteins are spliced together. Their finding, published in Cell Metabolism, may point toward novel targets for diabetes drugs.
Tale of Two Mice Pinpoints Major Factor for Insulin Resistance:
BOSTON – May 16, 2011 – The road to type 2 diabetes is paved with insulin resistance, a condition often associated with obesity in which the hormone begins to fail at its job helping to convert sugars to energy. Researchers at Joslin Diabetes Center have now identified an enzyme called PKC-delta as an important molecular modifier for development of insulin resistance, diabetes and fatty liver in mice. They also have found evidence suggesting a similar role for the enzyme in humans, making PKC-delta a promising new target for drugs for diabetes and related ailments.
Trigger Found for Autoimmune Heart Attacks:
BOSTON – March 23, 2011 – People with type 1 diabetes, whose insulin-producing cells have been destroyed by the body’s own immune system, are particularly vulnerable to a form of inflammatory heart disease (myocarditis) caused by a different autoimmune reaction. Scientists at Joslin Diabetes Center have revealed the exact target of this other onslaught, taking a large step toward potential diagnostic and therapeutic tools for the heart condition.
RETAIN Trial for Newly Diagnosed Type 1 Diabetes Enrolls Patients:
BOSTON and SEATTLE – March 2, 2011 – The Immune Tolerance Network (ITN) has enrolled the first participant in a two-part, phase II clinical research trial evaluating the effect of intravenous alpha 1-antitrypsin (AAT) on preserving the function of insulin-producing cells in patients recently diagnosed with type 1 diabetes. ARALAST NP is one marketed formulation of AAT. The Research Trial of ARALAST NP in New-onset Type 1 Diabetes (RETAIN) is seeking 82 eligible participants at 15 clinical research centers across the U.S. The first participant was enrolled at Emory University/Children’s Hospital of Atlanta.
Joslin Launches Initiative to Resolve the Critical Link Connecting CME to Sustained Quality Improvement:
BOSTON – March 2, 2011 – Joslin Diabetes Center has launched a groundbreaking initiative for primary care physicians to improve diabetes care. Joslin, with technology from Forward Health Group, Inc., is providing qualifying primary care practices in the United States with the critical capability to extract usefulness out of existing clinical data at the individual patient level, and to combine this information with practice improvement support and education. The initiative is supported via independent continuing medical education (CME) grant funding provided by GlaxoSmithKline and Merck & Co.
People at Risk of Diabetes Offer Clues Toward Novel Drugs:
BOSTON – February 14, 2011 – Once people develop type 2 diabetes, high blood glucose levels alter their metabolism so much that it becomes difficult to sift through all the clues to find what might enable the disease. “To identify factors that play a primary role in disease susceptibility, we want to investigate people before they get to that point,” says Mary-Elizabeth Patti, M.D. of Joslin Diabetes Center. By examining people across the spectrum of diabetes—from healthy to the full-blown disease—scientists in her lab have found a molecular pathway that offers novel targets for drugs.
Joslin’s Latino Diabetes Initiative Unveils Enhanced Website:
BOSTON – February 14, 2011 – Latinos are twice as likely to develop diabetes as Caucasians, and half the Latinos born in the United States in this century are expected to get the disease. Helping to meet this challenge, Joslin Diabetes Center’s Latino Diabetes Initiative—a comprehensive effort that combines clinical care, patient education, community outreach, research and healthcare team education—has upgraded its website with additional resources for Latinos with diabetes and their families in both English and Spanish.
Culprit Found for Increased Stroke Injury with Diabetes:
BOSTON – January 23, 2011 – Strokes that involve intracerebral hemorrhage (bleeding in the brain) are especially deadly, and there are no effective treatments to control such bleeding. Moreover, diabetes and hyperglycemia (high blood glucose levels) are associated with increases in bleeding during hemorrhagic stroke and worse clinical outcomes. But Joslin Diabetes Center researchers now have identified one key player that contributes to this increased bleeding, a discovery that may pave the way toward treatments that minimize adverse stroke outcomes.
Joslin, Kuwait’s Dasman Institute Forge Strategic Alliance:
BOSTON – December 21, 2010 – Joslin Diabetes Center and two other Harvard Medical School affiliates have launched a five-year strategic alliance with the Dasman Diabetes Institute for establishing a comprehensive and innovative program for diabetes care, management and research across Kuwait.
Beatson Foundation Gift Kicks Off Joslin WebCare Project for Managing Diabetes:
BOSTON – December 21, 2010 – Under a transformative $3.2 million donation from the Thomas J. Beatson, Jr. Foundation, Joslin Diabetes Center is taking the first major steps in creating Joslin WebCare, an ambitious project to bolster diabetes patient care and education through next-generation web services. The major gift also will underpin initiatives in caring for children with diabetes and for research aimed to guard against eye disease and other diabetes complications.
Study Identifies Cells that Give Rise to Brown Fat:
BOSTON – December 20, 2010 – In some adults, the white fat cells that we all stockpile so readily are supplemented by a very different form of fat—brown fat cells, which can offer the neat trick of burning energy rather than storing it. Researchers at Joslin Diabetes Center, which last year led the way in demonstrating an active role for brown fat in adults, now have identified progenitor cells in mouse white fat tissue and skeletal muscle that can be transformed into brown fat cells.
Joslin, Hallmark Health Sign Affiliation Agreement:
BOSTON – Dec. 20, 2010 — In response to the epidemic of diabetes in Massachusetts, Hallmark Health System, the leading provider of vital health services north of Boston, has joined forces with the Joslin Diabetes Center, the world’s preeminent diabetes research and clinical care organization.
Diabetes May Clamp Down on Brain Cholesterol:
BOSTON – November 30, 2010 – The brain contains more cholesterol than any other organ in the body, has to produce its own cholesterol and won’t function normally if it doesn’t churn out enough. Defects in cholesterol metabolism have been linked with Alzheimer’s disease and other neurodegenerative conditions. Now researchers at Joslin Diabetes Center have discovered that diabetes can affect how much cholesterol the brain can make.
Amy Wagers Receives Presidential Early Career Award:
BOSTON – November 8, 2010 – Amy Wagers, Ph.D., a Principal Investigator at Joslin Diabetes Center and Associate Professor of Stem Cell and Regenerative Biology at Harvard Medical School, has been given a Presidential Early Career Award for Scientists and Engineers. This is the highest honor bestowed by the United States government on science and engineering professionals in the early stages of their independent research careers.
Million-Dollar Gift Boosts Joslin Treatment for Children with Diabetes:
BOSTON – November 4, 2010 – Joslin Diabetes Center has received a $1 million gift that will broaden full access to pediatric clinical services for children with diabetes and their families. Given by the Thomas J. Beatson, Jr. Foundation, the donation will offer major support for the Joslin Pediatric, Adolescent and Young Adult Clinic’s care ambassador program.
Joslin Diabetes Center, SETMA Announce Affiliation:
BOSTON – November 1, 2010 – Joslin Diabetes Center, the world’s preeminent diabetes research and clinical care organization, has announced an affiliation with Southeast Texas Medical Associates (SETMA), LLP, in Beaumont, Texas. The Joslin Diabetes Center Affiliate at SETMA will offer some of the latest advances for treating diabetes and its complications as well as patient education and support services.
Joslin Physicians Hope to Teach Old Drug New Tricks:
BOSTON, Mass. – September 7, 2010 – An anti-inflammatory drug called salsalate, commonly given for arthritis pain, is being tested here to determine whether it can also help prevent cardiac disease. Steven Shoelson, M.D., Ph.D., and Allison Goldfine, M.D., who are affiliated with Joslin Diabetes Center and Harvard Medical School, are teaming up in translational research efforts taking laboratory observations into clinical study.
Barton Center for Diabetes Education Purchases Camp Joslin:
OXFORD, Mass., August 31, 2010 – The Barton Center for Diabetes Education, Inc. and Joslin Diabetes Center announce today that The Barton Center has purchased Camp Joslin, a camp for boys and young men with type 1 (insulin-dependent) diabetes. The Barton Center, which operates the nearby Clara Barton Camp for girls and young women with type 1 diabetes, will undertake a capital campaign to pay for improvements to Camp Joslin. The majority of the funds for the purchase came through an unrestricted grant from The Leona M. and Harry B. Helmsley Charitable Trust.
Study of Joslin Medalists Wins Beatson Challenge in Type 1 Diabetes Research:
BOSTON – August 12, 2010 – Two years ago, philanthropist Thomas J. Beatson, Jr. asked four Joslin Diabetes Center scientists to present him with compelling proposals for research on type 1 diabetes. Inspired by all four, in January 2009 he decided to help fund each, splitting a $1-million gift evenly between the four labs. An avid cyclist who has cycled more than 100,000 miles, Beatson added a rider to his gift: The first funded researcher to publish a paper with a significant outcome in a peer-reviewed journal would win the Beatson Challenge—and a special yellow cycling jersey. This week Hillary Keenan, Ph.D., a Joslin research associate, and her colleagues grabbed the jersey.
Ultimate Diabetes Survivors, the Joslin 50-Year Medalists, Give Clues to Cures:
BOSTON, Mass. – August 11, 2010 – In type 1 diabetes, the body relentlessly attacks and destroys its own insulin-producing pancreatic beta cells. But a study by Joslin Diabetes Center scientists now has firmly established that some of these cells endure for many decades in a small group of people with the disease—offering clues to potential treatments for preserving and even restoring the crucial cell population.
Joslin Diabetes Center, Cypress Fairbanks Announce Affiliation:
BOSTON, Mass. – August 9, 2010 – Joslin Diabetes Center, the world’s preeminent diabetes research and clinical care organization, has announced an affiliation with Cypress Fairbanks Medical Center Hospital in northwest Houston. The Joslin Diabetes Center Affiliate at Cypress Fairbanks Medical Center Hospital will offer some of the latest advances for treating diabetes and its complications as well as patient education and support services.
Joslin Announces Opportunity to Win Iacocca Silver 45th Anniversary Edition Ford Mustang:
BOSTON, Mass. – July 20, 2010 – The Mustang, the car that "changed everything" in the automotive industry, will now contribute to finding a cure for diabetes. Joslin Diabetes Center is raffling off a special edition of the famous "muscle" car – the Iacocca Silver 45th Anniversary Edition Ford Mustang. Only 45 of the limited edition Mustangs were made last year to honor the anniversary of the classic car’s introduction at the 1964 World’s Fair.
Joslin Shows Transplanted Beta Cells Learn to Deal with Stress:
BOSTON, Mass. - July 2, 2010 - For transplanted beta cells, life is tough. Not only are the insulin-producing cells in a stranger’s body, tucked into the liver rather than the pancreas, they are a bit short on oxygen and blood, and they are often exposed to raised levels of glucose. Joslin Diabetes Center scientists, however, have shown that the cells can protect themselves by actively adapting to their new homes—findings that may help to aid future transplants aimed at treating type 1 diabetes.
The Trouble with Tribbles in Diabetes:
BOSTON, Mass. – July 1, 2010 – Named for the furballs whose astonishing fecundity made them stars in early Star Trek episodes, the tribbles protein, first identified in fruit flies, aids in regulating many cell processes in humans. Joslin Diabetes Center researchers now have identified mechanisms triggered by a variant of the tribbles gene that cause trouble in insulin-producing pancreatic beta cells—and that offer a promising target for therapies for people with type 2 diabetes, even if they don’t carry that gene variant.
Joslin Diabetes Center Expands Pediatric Clinic:
BOSTON, Mass. – June 23, 2010 – Joslin Diabetes Center is opening an expanded version of its pediatric clinic, with enhancements that allow more optimal multi-disciplinary care for children, teens and young adults with diabetes and their families.
Facebook Game Helps People with Diabetes Improve Everyday Behaviors:
BERKELEY, Calif., and BOSTON, Mass. -- June 14, 2010 -- A new game called HealthSeeker(tm) launched today on Facebook(r), with the goal of helping players make specific lifestyle changes that focus on healthy eating. While the benefits of the game are available to anyone, HealthSeeker specifically helps people with diabetes make more informed lifestyle decisions in an innovative way that complements their daily use of social media.
Kuwait’s Dasman Institute Signs Agreement with Joslin Diabetes Center:
BOSTON, Mass. – May 5, 2010 – Joslin Diabetes Center has signed a pre-implementation agreement with the Dasman Institute for the Research, Training and Prevention of Diabetes and Related Disorders for establishing a comprehensive program for diabetes care, management and research across Kuwait. The parties, already working on needs assessment and planning for the program, expect to execute a five-year agreement in September.
Key Protein Links Insulin Action and Insulin Resistance in Diabetes:
BOSTON, Mass. – March 28, 2010 - Biologists have long known that an enzyme called the PI 3-kinase is a crucial actor in the main molecular pathway for insulin signaling in cells. Researchers at Joslin Diabetes Center now have uncovered startling evidence that one of the proteins in this enzyme also drives a pathway with an opposite result—triggering a stress response that leads to insulin resistance.
Joslin, AtlantiCare Announce Affiliation :
BOSTON, Mass. – March 23, 2010 – Joslin Diabetes Center, the world’s preeminent diabetes research and clinical care organization, has announced an affiliation with AtlantiCare, a regional healthcare organization based in Egg Harbor Township, New Jersey.
Generic Drug for Type 2 Diabetes Passes Next Clinical Hurdle:
BOSTON, Mass. – March 16, 2010 – Clinical studies of a generic drug called salsalate, widely prescribed for arthritis, now provide promising early results that it may be useful for the treatment of patients with type 2 diabetes as well. Salsalate is an atypical non-steroidal anti-inflammatory agent that is chemically similar to aspirin but a bit easier on the stomach. In a three-month trial of people with type 2 diabetes that was led by Joslin Diabetes Center researchers, those who took the drug showed significantly improved blood glucose levels.
Clinical Trial Compares Leading-Edge Treatments for Obesity and Diabetes:
BOSTON, Mass. – February 25, 2010 – Obesity is a major contributing factor to type 2 diabetes, a disease affecting more than 20 million people in the United States. For those who are overweight and have type 2 diabetes, weight loss lowers blood sugar levels and leads to improved health and better quality of life. However, it is difficult to lose weight and keep it off.
Joslin Study Finds Insulin Regulates Beta Cell Function in Healthy Humans :
BOSTON, Mass. – February 15, 2010 – In type 2 diabetes, which is occurring at alarming rates, the hormone insulin does not work effectively to lower blood sugars and patients also do not make enough insulin. These two processes have been widely considered as separate. However, a surprising discovery was made by Joslin Diabetes Center researchers in animal models of diabetes: insulin is important in regulating its own production. Confirming this discovery, Joslin clinical scientists have now gone on to show that when blood sugar levels rise in healthy people, insulin signals the cells that make insulin to increase their production.
Beta cells need key protein to divide and conquer diabetes:
BOSTON, Mass. – January 26, 2010 – In people who put on a lot of weight, or whose bodies start developing the inability to use insulin effectively that leads toward type 2 diabetes, the pancreas typically ramps up its supply of insulin-generating “beta” cells—at least in part by replication of existing beta cells. Researchers at Joslin Diabetes Center and their colleagues now have identified a cell-cycle protein that is essential for beta-cell replication to respond successfully to insulin resistance. The finding may point toward eventual therapies for preventing or treating type 2 diabetes.
Joslin Diabetes Center and dLife form new online partnership:
BOSTON – January 26, 2010 – joslin.org, the Internet site for Harvard-affiliated Joslin Diabetes Center, the world’s preeminent diabetes research and clinical care organization, and dLife.com, the leading online community for people living with diabetes, today announced a new online partnership. dLife will host a resource page on its web site featuring the clinical and research information from Joslin. Joslin will host on its website food and cooking videos from dLife’s award-winning TV show dLifeTV as well as links to relevant information on dLife.com.